Single-cell immune landscape of human atherosclerotic plaques
One of the classes of medications glucagon-like peptide-1 receptor agonists (GLP-1) treats Type 2 diabetes by stimulating insulin release by the pancreas, delaying gastric emptying, and decreasing the release of glucagon, a hormone in the body that raises blood sugar
And this is currently being investigated in Phase III under an FDA breakthrough designation. So maybe the glass is at least half full for semaglutide in treating NASH
Consult your physician if you have a personal or family history of Medullary Thyroid Carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
Your healthcare provider should tell you which WEGOVY product you will be using (for example single-dose pen or syringe, single-patient-use pen, or tablets)
The page leans into comparison and decision support and the details behind semaglutide, cost and coverage, provider access, safety and pharmacy quality